Guest guest Posted December 22, 2010 Report Posted December 22, 2010 Papers and articles, pertaining to Hepatic and Biliary Disorders, most read by your colleagues in the past 7 days A randomized controlled trial of high-dose ursodesoxycholic acid For nonalcoholic steatohepatitis (J Hepatol) Potency, safety and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection (J Hepatol) Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin (J Hepatol) Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy (J Hepatol) Platelet production and destruction in liver cirrhosis (J Hepatol) Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users (J Hepatol) Treatment of Chronic Hepatitis C Patients with the NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227) Leads to Robust Reductions in Viral RNA: A Phase 1b Multiple Ascending Dose Study (J Hepatol) Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation (Acta Pharmacol Sin) Bone Disorders in Chronic Liver Diseases (Curr Gastroenterol Rep) Chronic Hepatitis C infection, Insulin Resistance and Vascular Disease (Curr Pharm Des) More news... Quote
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.